Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state

This corrects the article DOI: 10.1038/ncomms14158.

[1]  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. , 1998, Pediatrics.

[2]  P. Kwong,et al.  Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes , 2011, Journal of Virology.

[3]  R. Hegele,et al.  Identification of nucleolin as a cellular receptor for human respiratory syncytial virus , 2011, Nature Medicine.

[4]  Austin Hughes,et al.  A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks , 1995, Nature.

[5]  L. Gutshall,et al.  Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. , 2007, The Journal of general virology.

[6]  L. Wyns,et al.  Comparison of llama VH sequences from conventional and heavy chain antibodies. , 1997, Molecular immunology.

[7]  R. Plemper,et al.  A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. , 2012, Virology.

[8]  J. Pascale,et al.  Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution? , 2015, Journal of Virology.

[9]  J. Gettemans,et al.  Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer , 2016, EBioMedicine.

[10]  W. Fiers,et al.  Structure of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus in Complex with a Protective Monoclonal Antibody , 2015, Journal of Virology.

[11]  U. Baxa,et al.  Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein , 2015, PLoS pathogens.

[12]  S. Madhi,et al.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis , 2010, The Lancet.

[13]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[14]  S. Feldman,et al.  The Fusion Glycoprotein of Human Respiratory Syncytial Virus Facilitates Virus Attachment and Infectivity via an Interaction with Cellular Heparan Sulfate , 2000, Journal of Virology.

[15]  P. Collins,et al.  Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. , 2001, Virology.

[16]  D. Pfarr,et al.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. , 1997, The Journal of infectious diseases.

[17]  C. Palomo,et al.  Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection , 2015, Antimicrobial Agents and Chemotherapy.

[18]  Owen Johnson,et al.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM , 2011, Acta crystallographica. Section D, Biological crystallography.

[19]  J. Dopazo,et al.  Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein , 1994, Journal of virology.

[20]  F. Baldanti,et al.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody , 2013, Nature.

[21]  W. P. Glezen,et al.  Risk of primary infection and reinfection with respiratory syncytial virus. , 1986, American journal of diseases of children.

[22]  R. Lockey,et al.  Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. , 2001, Biochemical and biophysical research communications.

[23]  J. Grooten,et al.  Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastoris , 2009, BMC biotechnology.

[24]  B. Graham,et al.  Challenges and Opportunities for Respiratory Syncytial Virus Vaccines , 2013, Current Topics in Microbiology and Immunology.

[25]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[26]  L. Kwanten,et al.  Molecular mechanism of respiratory syncytial virus fusion inhibitors. , 2016, Nature chemical biology.

[27]  J. Skehel,et al.  Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Schwartz,et al.  Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. , 2001, The Journal of allergy and clinical immunology.

[29]  S S Whitehead,et al.  Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. de Bleser,et al.  Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. , 2011, The Journal of infectious diseases.

[31]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination , 2022 .

[32]  L. Wyns,et al.  Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Palomo,et al.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention , 2012, Proceedings of the National Academy of Sciences.

[34]  G. Chuang,et al.  Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera , 2015, Science Translational Medicine.

[35]  A. D. de Fougerolles,et al.  Nanobodies®† as inhaled biotherapeutics for lung diseases , 2017, Pharmacology & therapeutics.

[36]  M. Desai,et al.  Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. , 2015, Journal of medicinal chemistry.

[37]  G. Fuh,et al.  Erratum: Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation , 2016, Nature Medicine.

[38]  Philip R. Evans,et al.  How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.

[39]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[40]  Herren Wu,et al.  Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. , 2007, Journal of molecular biology.

[41]  Cinque S. Soto,et al.  Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.

[42]  Rosanna Lagos,et al.  Motavizumab Treatment of Infants Hospitalized With Respiratory Syncytial Virus Infection Does Not Decrease Viral Load or Severity of Illness , 2014, The Pediatric infectious disease journal.

[43]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[44]  P. Lemey,et al.  The Comparative Genomics of Human Respiratory Syncytial Virus Subgroups A and B: Genetic Variability and Molecular Evolutionary Dynamics , 2013, Journal of Virology.

[45]  B. '. ’t Hart,et al.  The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis , 2015, Arthritis Research & Therapy.

[46]  W. Giang,et al.  Condensed protocol for competent cell preparation and transformation of the methylotrophic yeast Pichia pastoris. , 2005, BioTechniques.